HeraMED

HeraMED EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of HeraMED (HMD.AX) as of Oct 26, 2026 is -8.64. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -7.66 — a change of 12.69% (lower).

EV/FCF

-8.64

YoY

12.69%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of HeraMED is 2024 -8.64 . EV/FCF (Enterprise Value to Free Cash Flow) of HeraMED was 2023 -7.66 . It decreases by 12.69% lower compared to the previous year.

The HeraMED EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-32.28 AUD
Jan 1, 2018
-20.92 AUD
Jan 1, 2019
-14.98 AUD
Jan 1, 2020
-15.05 AUD
Jan 1, 2021
-8.96 AUD
Jan 1, 2022
-8.23 AUD
Jan 1, 2023
-7.66 AUD
Jan 1, 2024
-8.64 AUD
The HeraMED EV/FCF history
YEAREV/FCFYoY
-8.64+12.69%
-7.66-6.89%
-8.23-8.14%
-8.96-40.46%
-15.05+0.44%
-14.98-28.37%
-20.92-35.20%
-32.28+29.24%
-24.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HeraMED Stock analysis

What does HeraMED do? HeraMED Ltd. generates revenue through the sale of hardware solutions and related software applications. Its flagship product, HeraBEAT, is a medical-grade, clinically-validated connected Ultrasound Fetal Doppler device designed for expectant mothers to self-monitor their fetus' heart rate at home. The device connects via Bluetooth Low Energy to smartphones, transmitting data to a dedicated app that displays readings. The company also offers a homecare pregnancy solution service, leveraging AI and machine-learning algorithms to analyze fetal data and provide insights to healthcare professionals or home users. Sales are primarily directed to expectant mothers seeking home monitoring tools and healthcare providers integrating these solutions into patient care. HeraBEAT is marketed as a clinically-validated tool for home use, distinguishing it from standard consumer devices. The product’s integration with smartphone applications enables real-time data access, appealing to tech-savvy parents. The homecare pregnancy solution complements the hardware by offering ongoing support through AI-driven analysis, enhancing user engagement and retention. Healthcare professionals benefit from the data insights provided, potentially incorporating HeraBEAT into routine prenatal care protocols. The company’s revenue streams are built around direct sales of HeraBEAT devices and subscription-based services tied to the homecare solution. Expectant mothers purchase the hardware and access the software interface, while healthcare providers may adopt the service model for patient monitoring. AI and machine-learning capabilities are embedded in the product offering, positioning HeraMED as a provider of both medical devices and data-driven health services. HeraMED is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HeraMED stock

EV/FCF (Enterprise Value to Free Cash Flow) of HeraMED is -8.64 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of HeraMED changed from -7.66 to -8.64, representing a 12.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) HeraMED since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s HeraMED with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — HeraMED

All Key Metrics — HeraMED